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Abstract. Background: The frequency of epithelial cell
adhesion molecule (EpCAM) expression was investigated in
non-small cell lung cancer (NSCLC) cells and human
tissues, and its clinicopathological significance in
adenocarcinoma of the lung was evaluated. Materials and
Methods: EpCAM expression was analysed by reverse
transcription-polymerase chain reaction (RT-PCR) and flow
cytometry in human NSCLC cells. EpCAM protein expression
was evaluated in 234 adenocarcinoma tissues using
immunohistochemistry. Results: A high expression level of
EpCAM was observed in human NSCLC cells by flow
cytometry and RT-PCR. EpCAM overexpression was detected
in 120/234 (51.3% ) surgically resected adenocarcinoma
tissues. EpCAM overexpression occurred significantly more
frequently in adenocarcinoma than in bronchioloalveolar
carcinoma (p=0.02). The overall survival did not differ
significantly between EpCAM-overexpressing and EpCAM-
negative patients (p=0.40). Conclusion: These findings
suggest EpCAM plays a role in the carcinogenesis of
adenocarcinoma of the lung and might provide a promising
molecule for targeted therapy in NSCLC.
Lung cancer is the most common cause of cancer-related
death worldwide and almost 80%  of lung cancers can be
classified as non-small cell lung cancer (NSCLC) (1).
Despite several improvements in the treatment for NSCLC,
the prognosis and outcome of patients with NSCLC remains
unfavourable and the 5-year overall survival (OS) rate is 14-
17%  (2). Most post-surgical relapses are represented by
distant metastases and the risk of a local recurrence is less
than 10% . Although several recent randomized studies of
adjuvant chemotherapy in completely resected NSCLC
showed partially conflicting results, they also indicated a
benefit of adjuvant chemotherapy of about 5%  at 5 years (3-
6). Recent advances in molecular technologies have
facilitated the search for genes that are overexpressed in
cancers, which might serve as novel targets for cancer
treatment.
Epithelial cell adhesion molecule (EpCAM) is a type I
transmembrane glycoprotein of about 40 kDa that is
expressed on the basolateral surface of most normal
epithelial tissues such as the colon, gastric, prostate, and
lung epithelia (7). EpCAM is involved in intercellular
adhesion and interacts with E-cadherin to induce cell
adhesion (8). EpCAM is overexpressed in a variety of
epithelial tumours such as breast cancer, gastric cancer,
oesophageal cancer and prostate cancer (9-12). Munz et al.
reported recently that EpCAM overexpression is linked
directly to stimulation of the cell cycle and proliferation by
upregulating c-myc and cyclin A/E (13). In breast cancer
cells, inhibition of EpCAM expression by small inhibitory
RNA diminishes cell proliferation, migration and
invasiveness (14). However, the relationship between
EpCAM overexpression and the invasiveness or metastatic
ability of cancer cells and the underlying molecular
mechanism remain unclear.
Although a high expression level of EpCAM has been
reported in NSCLC, the clinical implication has not been
determined fully (9, 15). This study was conducted to
investigate the frequency of EpCAM expression in NSCLC
cells and human tissues, and to evaluate the
clinicopathological significance of EpCAM expression in
adenocarcinoma of the lung.
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Materials and Methods
Cell lines. The human NSCLC cell lines A549, PC14PE6, NCI-
H661m and NCI-H520, and the human kidney epithelial cell line,
HEK-293, were obtained from the American Type Culture
Collection (ATCC, Manassa, VA, USA); HEK-293 cells were used
as the control and were propagated in minimum essential medium
supplemented with 10%  fetal bovine serum (Gibco, Grand Island,
NY, USA), 100 units/mL of penicillin (base), 100 mg/mL of
streptomycin (base) and 25 ng/mL of amphotericin B. H661 cells
were propagated in Dulbecco’s modified Eagle’s medium and A549,
PC14PE6 and H520 cells were propagated in RPMI1640.
Flow cytometry. Flow cytometric analysis of cancer cells was
performed on a FACS-vantage (Becton-Dickinson, Mountain View,
CA, USA). Five hundred thousand NSCLC cells were cultured and
prepared in a single cell suspension. One millilitre of cell
suspension was stained with fluorescein isothiocyanate (FITC)-
labelled anti-EpCAM antibody (Abcam, Cambridge, UK). Ten
thousand cells were analysed, and the data were collected and
analysed using Cell Quest software. 
Patients and tissue specimens. Paraffin-embedded sections were
obtained from surgical specimens of 234 patients with
adenocarcinoma who underwent curative surgery at Samsung
Medical Center between January 2000 and December 2002. The
tumour stage was classified according to the TNM classification.
Immunofluorescent staining of EpCAM. For immunofluorescent
labelling of EpCAM in the explants, fixed explants were rinsed in
phosphate-buffered saline (PBS) supplemented with bovine serum
albumin (BSA), rinsed twice in PBS-BSA supplemented with
0.05%  Tween 20 and then rinsed once in PBS-BSA. The explants
were incubated with 3%  BSA in PBS to reduce non-specific
labelling. The excess BSA was removed and the explants were
incubated overnight a 4˚C with FITC-conjugated antibody to
EpCAM (Abcam). The explants were rinsed with PBS, mounted,
and examined using a fluorescence microscopy.
Reverse transcription-polymerase chain reaction (RT-PCR). Total
RNA was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA,
USA), and cDNA was synthesized from 2 μg of total RNA using
an Oligo(dT) primer (Invitrogen) and Omniscript Reverse
Transcription kit (Qiagen, Valencia, CA, USA). β-Actin was used
as the endogenous expression standard. Each PCR program involved
a 3 min initial denaturation step at 94˚C, followed by 25 cycles at
94˚C for 30s, 55˚C for 30s and 72˚C for 1min on a gradient thermal
cycler (Biometer, Göttingen, Germany). The primer sequences were:
EpCAM forward, 5’GAA GGC TGA GAT AAA GGA GAT GGG3’
and EpCAM reverse, 5’TTA ACG ATG GAG TCC AAG TTC
TGG3’.
Immunohistochemistry for EpCAM expression in lung adenocarcinoma
tissues. Formalin-fixed paraffin-embedded tissue blocks were
sectioned to 4 μm thickness. The tissue sections were deparaffinized in
xylene and then rehydrated in serially graded alcohol. Endogenous
peroxidase activity was eliminated by preincubation in 3%  hydrogen
peroxide in 10%  methanol for 15 min followed by three washes in
PBS. For antigen retrieval, the sections were heated in microwave oven
for 10 min in 10 mM sodium citrate buffer (pH 6.0). After washing in
Tris-buffered saline, each slide was preincubated in 100 μL of 5%
normal blocking solution (goat serum) for 10 min to reduce non-
specific binding. The slides were incubated at room temperature with
mouse monoclonal antibody to epidermal growth factor receptor
(EGFR) (NCL-EGFR-384; Novocastra, Newcastle, UK) at 1:100 in a
humid chamber for 1 h. The primary antibody was visualized with an
avidin–biotin complex system (Dako, Glostrup, Denmark).
The immunohistochemical evaluation was performed
independently by two pathologists with no prior knowledge of the
clinical data. EpCAM expression was evaluated by calculating the
total immunostaining score as the product of the proportion score
and the intensity score. The proportion score described the estimated
fraction of positively stained tumour cells (0, none; 1 <10% ; 2, 10-
50% ; 3, 50-80% ; and 4, >80% ). The intensity score represented
the estimated staining intensity (0, no staining; 1, weak; 2,
moderate; and 3, strong). The total score ranged from 0 to 12. The
overexpression of EpCAM was defined as a total score >4 as
described previously (16).
Statistical analysis. The clinical and pathological variables were
compared between groups using the Pearson χ2-square test for
categorical variables. Survival curves were calculated using the
Kaplan–Meier method and compared with other prognostic variables
using the log-rank test. Stepwise Cox regression analysis was
performed to identify prognostic factors for survival. In all tests,
p<0.05 was considered significant.
Results
EpCAM expression in non-small cell lung cancer cells. Four
different NSCLC cell lines were chosen to study the
expression level of EpCAM. The expression of EpCAM
mRNA was detected in two of these NSCLC cell lines, NCI-
H520 and NCI-H661. However, EpCAM mRNA was not
detected in another NSCLC cell line, PC14PE6, and was
detected only modestly in the A549 cell line (Figure 1).
EpCAM protein expression at the cell surface was analysed
by flow cytometry using fluorescently labelled EpCAM
antibody. Consistent with the pattern of EpCAM transcript
level, EpCAM protein was strongly detected in H520 and
H661 cell lines, and weakly detected in A549 cells.
PC14PE6 and HEK293 kidney epithelial cells did not
express a detectable level of EpCAM protein at the cell
surface (Figure 2). In cell culture slides examined immuno-
cytochemically with fluorescently labelled EpCAM antibody,
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Figure 1. mRNA expression levels of EpCAM and β-actin as a control
were assessed in the indicated carcinoma cell lines by standard RT-PCR.
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Figure 2. Cell surface expression of EpCAM was analysed by flow cytometry of the indicated cell lines.
Figure 4. Examples of EpCAM immunohistochemical staining of lung cancer samples. High EpCAM reactivity was detected mainly at the cell surface
of the tumour tissue.
Figure 3. Expression of EpCAM protein in NCI-H520 and NCI-H661 cell lines was analysed by immunofluorescence staining.
EpCAM immunoreactivity was confined mainly to the cell
surface of EpCAM-positive cancer cell lines (Figure 3).
EpCAM expression in surgically resected adenocarcinoma of
lung. EpCAM expression was assessed by immunohisto-
chemical staining of the primary tumour specimens obtained
from patients (Figure 4). EpCAM expression at any
expression level was observed in 51.3%  (120/234) of
patients. Interestingly, positive focal EpCAM staining was
also seen in the normal bronchial epithelium. However, only
27.3%  (64/234) of tumours displayed overexpression of
EpCAM, which was defined as a total score >4.
Clinicopathological parameters such as sex, age, T stage or
regional lymph node metastasis were not related to EpCAM
expression (Table I). However, EpCAM overexpression was
significantly more frequent in adenocarcinoma specimens
than in bronchioloalveolar carcinoma (BAC) of the lung
specimens (p=0.02). For the total study population, the
median follow-up was 82.0 months (range, 66.1-104.2
months) and the median OS was 76.0 months (95%  CI,
61.5-90.5 months). The OS did not differ significantly
between the EpCAM-overexpressing and EpCAM-negative
groups (72.1 vs. 78.0 months, p=0.40; Figure 5). The
disease-free survival did not differ significantly between the
two groups (p=0.63, data not shown).
Discussion
In this study, EpCAM was expressed robustly at the
transcriptional and protein expression levels in several
NSCLC cell lines. Immunohistochemistry showed that
EpCAM proteins were localized at the cell surface
membrane. In primary tumour specimens, EpCAM
expression at any expression level was observed in 51.3%  of
adenocarcinoma patients. However, the pattern of EpCAM
expression was heterogeneous at all expression levels. The
overexpression of EpCAM was noted in only 27.3%
(64/234) of tumours after definition of the overexpression of
EpCAM as a total score >4. The frequency of EpCAM
expression observed in this study is consistent with or
slightly lower than those of other recent EpCAM studies of
various human tumour samples. In the retrospective analysis
of thousands of samples from prostate, lung, colon, gastric
and renal cell cancer patients using standardized staining
conditions in tissue microarray (9), about 85%  of
adenocarcinomas and 72%  of squamous cell carcinomas
overexpressed EpCAM in a homogeneous manner. In the
subset of lung cancer array of this study, 823 of 1287 cases
(63.9% ) showed a high level EpCAM expression (9).
Interestingly, a significantly higher frequency of EpCAM
overexpression was found in adenocarcinoma compared with
BAC. BAC is a subtype of lung adenocarcinoma without
evidence of stromal, vascular or pleural invasion and is
thought to be a less aggressive in situ carcinoma than
adenocarcinoma. EpCAM expression might play a role in the
carcinogenesis of adenocarcinoma of the lung. However, no
significant difference was found in lymph node metastasis or
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Table Ι. Patients characteristics according to EpCAM expression in
adenocarcinoma.




<61 115 88 27 0.19
≥61 119 82 37
Gender
Male 127 88 39 0.21
Female 107 82 25
Histology
Adenocarcinoma 199 139 60 0.02
BAC or BAC combined 35 31 4
Primary tumor
pT1 65 44 21 0.29
pT2-T4 (T2/T3/T4) 169 (137/16/16) 126 43
LN status
pN0 160 112 48 0.18
pN1-N2 (N1/N2/N3) 74 (34/39/1) 58 16
Stage
I (A/B) 51/92 102 41 0.78
II (A/B) 5/30 27 8
III (A/B/IV) 38/16/2 41 15
*BAC: bronchioloalveolar carcinoma.
Figure 5. Overall survival according to the EpCAM expression level in
patients with lung adenocarcinoma who underwent surgical resection.
stage between the EpCAM-overexpressing and EpCAM-
negative group. Further studies are needed to determine the
exact role of EpCAM expression in terms of the invasiveness
or metastatic ability in adenocarcinoma of the lung.
Given the possible prognostic significance of EpCAM
overexpression in cancers suggested by several investigators
(10, 11, 14, 16), whether survival differed according to
EpCAM expression level was also assessed. No significant
difference was found in disease-free survival or OS between
the EpCAM-overexpressing and EpCAM-negative groups,
suggesting that EpCAM overexpression has no prognostic
significance. The results are consistent with previous reports
showing no definite correlations between EpCAM expression
and tumour grade or OS in any of the histological entities
(9,15). The prognostic impact of EpCAM overexpression on
survival varies widely between studies of various tumours.
In human breast cancer, for example, the expression of
EpCAM was negatively correlated with survival parameters
in node-positive patients (18). A similar negative correlation
was observed in patients with gall bladder cancer (19) and
oesophageal cancer (10). In contrast, EpCAM upregulation
was associated with improved survival in patients with clear
cell renal carcinoma (17), moderately differentiated stage II
colon cancer (9) and NSCLC at stage pT2 (9). These
discordant findings with different cancer types might be
attributable to several factors. Possible explanations include
the limitations of the semi-quantitative nature of
immunohistochemical staining, such as the different
antibodies used, interobserver or intraobserver variation, and
the variable cut-off values for EpCAM positivity. In many
cases, the studies were performed on a relatively small
sample size, which may have been insufficient to show
significant differences. A standardized method remains to be
established and validated in larger series of patients in
prospective studies.
It is also possible that the functions and actions of
EpCAM in cancer progression may differ in different tissue
microenvironments. Although an in vitro study showed rapid
upregulation of c-myc by EpCAM overexpression,
suggesting a direct link between EpCAM and c-myc-
mediated cell cycle control (13), the exact mechanism
responsible for the contribution of EpCAM to the malignant
potential of tumour cells is not understood fully.
Despite the controversy about the clinicopathological
significance of EpCAM expression in human malignancies, the
various EpCAM studies are consistent in showing the frequent,
high level of expression of EpCAM in diverse human cancers.
This observation makes EpCAM a prime target for
immunotherapies using antibodies to EpCAM to treat several
cancers. Monoclonal antibodies (e.g., edrecolomab, adecatu-
mumab), EpCAM-specific immunotoxins (e.g., proxinium),
multi-target-specific EpCAM antibodies (e.g., catumaxomab)
and various EpCAM cancer vaccines are being investigated in
ongoing clinical trials (18) and have shown partial activity in
several tumour types.
The validation of EpCAM as a therapeutic cancer target
remains largely unexplored. The precise understanding of the
molecular role of EpCAM in tumour progression will be
crucial in rationalizing the various clinical attempts to
employ EpCAM-specific antibodies and in identifying
subsets of patients who would benefit most from EpCAM-
targeted cancer therapy. In parallel with a number of
EpCAM-directed immunotherapies, the focus of future
EpCAM studies will be on elucidating EpCAM signalling
networks, determining its oncogenic or metastatic capacities
in relation to other membrane proteins and identifying its
possible role in contributing to cancer cell “stemness”.
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